Modulating the Endocannabinoid System in Human Health and Disease--successes and Failures

Overview

Journal FEBS J

Specialty Biochemistry

Date 2013 Apr 5

PMID 23551849

Citations 159

Authors

Pal Pacher

George Kunos

Affiliations

Soon will be listed here.

Abstract

The discovery of the endocannabinoid system, comprising the G-protein coupled cannabinoid 1 and 2 receptors (CB1/2), their endogenous lipid ligands or endocannabinoids, and synthetic and metabolizing enzymes, has triggered an avalanche of experimental studies implicating the endocannabinoid system in a growing number of physiological/pathological functions. These studies have also suggested that modulating the activity of the endocannabinoid system holds therapeutic promise for a broad range of diseases, including neurodegenerative, cardiovascular and inflammatory disorders; obesity/metabolic syndrome; cachexia; chemotherapy-induced nausea and vomiting; and tissue injury and pain, amongst others. However, clinical trials with globally acting CB1 antagonists in obesity/metabolic syndrome, and other studies with peripherally-restricted CB1/2 agonists and inhibitors of the endocannabinoid metabolizing enzyme in pain, have introduced unexpected complexities, suggesting that a better understanding of the pathophysiological role of the endocannabinoid system is required to devise clinically successful treatment strategies.

Citing Articles

Discovery of Peptidic Siderophore Degradation by Screening Natural Product Profiles in Marine-Derived Bacterial Mono- and Cocultures.

Monge-Loria M, Zhong W, Abrahamse N, Hartter S, Garg N Biochemistry. 2025; 64(3):634-654.

PMID: 39807563 PMC: 11800396. DOI: 10.1021/acs.biochem.4c00706.

Cannabinoids: Role in Neurological Diseases and Psychiatric Disorders.

Kumar U Int J Mol Sci. 2025; 26(1.

PMID: 39796008 PMC: 11720483. DOI: 10.3390/ijms26010152.

Knowledge, opinions and experiences of nurses and nursing students in Portugal regarding the use of medical Cannabis.

Paiva C, Santos T, Cunha-Oliveira A, Rosendo I, Pita J BMC Nurs. 2024; 23(1):788.

PMID: 39468501 PMC: 11520810. DOI: 10.1186/s12912-024-02443-5.

The Role of Host Genetics and Intestinal Microbiota and Metabolome as a New Insight into IBD Pathogenesis.

Zakerska-Banaszak O, Zuraszek-Szymanska J, Eder P, Ladziak K, Slomski R, Skrzypczak-Zielinska M Int J Mol Sci. 2024; 25(17).

PMID: 39273536 PMC: 11394875. DOI: 10.3390/ijms25179589.

Investigating the Role of Cannabinoid Type 1 Receptors in Vascular Function and Remodeling in a Hypercholesterolemic Mouse Model with Low-Density Lipoprotein-Cannabinoid Type 1 Receptor Double Knockout Animals.

Vass Z, Shenker-Horvath K, Banyai B, Veto K, Torok V, Gem J Int J Mol Sci. 2024; 25(17).

PMID: 39273484 PMC: 11395437. DOI: 10.3390/ijms25179537.

References

Elmes S, Jhaveri M, Smart D, Kendall D, Chapman V . Cannabinoid CB2 receptor activation inhibits mechanically evoked responses of wide dynamic range dorsal horn neurons in naïve rats and in rat models of inflammatory and neuropathic pain. Eur J Neurosci. 2004; 20(9):2311-20. DOI: 10.1111/j.1460-9568.2004.03690.x. View

Rosenstock J, Hollander P, Chevalier S, Iranmanesh A . SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes. Diabetes Care. 2008; 31(11):2169-76. PMC: 2571069. DOI: 10.2337/dc08-0386. View

Pisanti S, Bifulco M . Endocannabinoid system modulation in cancer biology and therapy. Pharmacol Res. 2009; 60(2):107-16. DOI: 10.1016/j.phrs.2009.03.011. View

Mulvihill M, Nomura D . Therapeutic potential of monoacylglycerol lipase inhibitors. Life Sci. 2012; 92(8-9):492-7. PMC: 3594462. DOI: 10.1016/j.lfs.2012.10.025. View

Gunduz-Cinar O, MacPherson K, Cinar R, Gamble-George J, Sugden K, Williams B . Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity. Mol Psychiatry. 2012; 18(7):813-23. PMC: 3549323. DOI: 10.1038/mp.2012.72. View

Piro J, Benjamin D, Duerr J, Pi Y, Gonzales C, Wood K . A dysregulated endocannabinoid-eicosanoid network supports pathogenesis in a mouse model of Alzheimer's disease. Cell Rep. 2012; 1(6):617-23. PMC: 3715876. DOI: 10.1016/j.celrep.2012.05.001. View

Atwood B, Wager-Miller J, Haskins C, Straiker A, Mackie K . Functional selectivity in CB(2) cannabinoid receptor signaling and regulation: implications for the therapeutic potential of CB(2) ligands. Mol Pharmacol. 2011; 81(2):250-63. PMC: 3263955. DOI: 10.1124/mol.111.074013. View

Cravatt B, Demarest K, Patricelli M, Bracey M, Giang D, Martin B . Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A. 2001; 98(16):9371-6. PMC: 55427. DOI: 10.1073/pnas.161191698. View

Kimball E, Schneider C, Wallace N, Hornby P . Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium. Am J Physiol Gastrointest Liver Physiol. 2006; 291(2):G364-71. DOI: 10.1152/ajpgi.00407.2005. View

10.

Kunos G, Tam J . The case for peripheral CB₁ receptor blockade in the treatment of visceral obesity and its cardiometabolic complications. Br J Pharmacol. 2011; 163(7):1423-31. PMC: 3165952. DOI: 10.1111/j.1476-5381.2011.01352.x. View

11.

Murikinati S, Juttler E, Keinert T, Ridder D, Muhammad S, Waibler Z . Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment. FASEB J. 2009; 24(3):788-98. DOI: 10.1096/fj.09-141275. View

12.

Mechoulam R, Parker L . The endocannabinoid system and the brain. Annu Rev Psychol. 2012; 64:21-47. DOI: 10.1146/annurev-psych-113011-143739. View

13.

Steffens S, Pacher P . Targeting cannabinoid receptor CB(2) in cardiovascular disorders: promises and controversies. Br J Pharmacol. 2012; 167(2):313-23. PMC: 3481040. DOI: 10.1111/j.1476-5381.2012.02042.x. View

14.

Maresz K, Pryce G, Ponomarev E, Marsicano G, Croxford J, Shriver L . Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med. 2007; 13(4):492-7. DOI: 10.1038/nm1561. View

15.

Wang H, Dey S, Maccarrone M . Jekyll and hyde: two faces of cannabinoid signaling in male and female fertility. Endocr Rev. 2006; 27(5):427-48. DOI: 10.1210/er.2006-0006. View

16.

Mukamal K, MacLure M, Muller J, Mittleman M . An exploratory prospective study of marijuana use and mortality following acute myocardial infarction. Am Heart J. 2008; 155(3):465-70. PMC: 2276621. DOI: 10.1016/j.ahj.2007.10.049. View

17.

Palkovits M, Harvey-White J, Liu J, Kovacs Z, Bobest M, Lovas G . Regional distribution and effects of postmortal delay on endocannabinoid content of the human brain. Neuroscience. 2008; 152(4):1032-9. PMC: 2655344. DOI: 10.1016/j.neuroscience.2008.01.034. View

18.

Scott D, Wright C, Angus J . Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat. Pain. 2004; 109(1-2):124-31. DOI: 10.1016/j.pain.2004.01.020. View

19.

Benito C, Romero J, Tolon R, Clemente D, Docagne F, Hillard C . Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. J Neurosci. 2007; 27(9):2396-402. PMC: 6673484. DOI: 10.1523/JNEUROSCI.4814-06.2007. View

20.

Cappellano G, Uberti F, Caimmi P, Pietronave S, Mary D, Dianzani C . Different expression and function of the endocannabinoid system in human epicardial adipose tissue in relation to heart disease. Can J Cardiol. 2012; 29(4):499-509. DOI: 10.1016/j.cjca.2012.06.003. View